Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Condition:   Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Intervention:   Drug: SC291 Sponsor:   Sana Biotechnology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials